| A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo (NCT07712523) | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | 2025-11-05 |
| A Study of LAD191 in Adults With Hidradenitis Suppurativa (NCT07151937) | Almirall, S.A. | 2025-11-05 |
| A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. (NCT07258979) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2025-11-05 |
| 18F-mFBG Imaging for Myocardial Sympathetic Innervation (NCT06965621) | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | 2025-11-05 |
| Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment (NCT07238881) | Sun Yat-sen University | 2025-11-05 |
| A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection (NCT07245953) | Suzhou HepaThera Biotech Co., Ltd. | 2025-11-05 |
| Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial (NCT07202247) | City of Hope Medical Center | 2025-11-05 |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) (NCT07100080) | Bristol-Myers Squibb | 2025-11-05 |
| Lamivudine as a Novel Clinical Effort for Rett Syndrome (NCT07640503) | Maria Denise Fernandes Carvalho de Andrade | 2025-11-05 |
| Corticosteroid Against Saline Injections for Thumb Osteoarthritis (CASITOA) (NCT06401317) | Université du Québec à Trois-Rivières | 2025-11-04 |
| A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis (NCT07121413) | Shanghai Synvida Biotechnology Co.,Ltd. | 2025-11-04 |
| AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC) (NCT07544784) | Fudan University | 2025-11-04 |
| Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy (NCT07347314) | National Cancer Center, Japan | 2025-11-04 |
| Tau PET Outcomes With Anti-amyloid Immunotherapies (NCT06723015) | Mayo Clinic | 2025-11-04 |
| PULSAR Combined With Immunotherapy and Chemotherapy (NCT07291947) | Wang Xin | 2025-11-04 |
| Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging (NCT07225114) | UNC Lineberger Comprehensive Cancer Center | 2025-11-04 |
| Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma (NCT07245368) | Prana Therapies Inc | 2025-11-04 |
| Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors (NCT07243470) | Centre Leon Berard | 2025-11-04 |
| Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (NCT07315854) | Beijing Friendship Hospital | 2025-11-04 |
| Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu (NCT07203378) | University of Utah | 2025-11-04 |
| Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (NCT07223424) | Diwakar Davar | 2025-11-04 |
| POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions (NCT07220720) | University of Florida | 2025-11-04 |
| Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity (NCT07245771) | Ikaria Bioscience Pty Ltd | 2025-11-04 |
| A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse (NCT07223840) | Eli Lilly and Company | 2025-11-03 |
| IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation (NCT07198841) | Guangdong Association of Clinical Trials | 2025-11-03 |
| Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta (NCT07108153) | Sionna Therapeutics Inc. | 2025-11-03 |
| Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis (NCT06567717) | Cedars-Sinai Medical Center | 2025-11-03 |
| Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer (NCT07325630) | Zhejiang Cancer Hospital | 2025-11-03 |
| Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial (NCT07263438) | Centre Hospitalier Universitaire Vaudois | 2025-11-03 |
| Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial (NCT07264686) | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 2025-11-03 |
| DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI (NCT07162506) | Tianjin Medical University Cancer Institute and Hospital | 2025-11-03 |
| A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa (NCT07287644) | Bluefin Biomedicine, Inc. | 2025-11-03 |
| TRPM8 Activators for Peripheral Neuropathy (NCT07583797) | SHIANG-SUO HUANG | 2025-11-03 |
| A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease (NCT07203001) | Novartis Pharmaceuticals | 2025-11-03 |
| A Study of Zasocitinib in Adults With Nonsegmental Vitiligo (NCT07108283) | Takeda | 2025-11-03 |
| Fentanyl Versus Hydromorphone in Patients on Mechanical Ventilation (NCT07224620) | Beth Israel Deaconess Medical Center | 2025-11-03 |
| Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED). (NCT07264517) | Instituto Grifols, S.A. | 2025-11-03 |
| Targeted Naltrexone to Support Individuals Participating in Dry January (NCT07132177) | Brigham and Women's Hospital | 2025-11-03 |
| Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis (NCT07228325) | Nasus Pharma | 2025-11-03 |
| Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults (NCT07215520) | CastleVax Inc. | 2025-11-03 |
| Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies (NCT07014319) | Seoul National University Hospital | 2025-11-03 |
| Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery (NCT07032792) | Northwell Health | 2025-11-03 |
| Management of Iron Deficiency Anemia in Hemodialysis Patients (NCT07706582) | Beni-Suef University | 2025-11-02 |
| Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers (NCT05835804) | Centre Hospitalier Universitaire, Amiens | 2025-11-01 |
| Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists (NCT07221461) | Goldman, Butterwick, Fitzpatrick and Groff | 2025-11-01 |
| A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER (NCT07101848) | Hospital Israelita Albert Einstein | 2025-11-01 |
| Evaluating the Efficacy and Safety of Modified Qing-Zao-Jiu-Fei Decoction on Pneumoconiosis Patients (NCT07178184) | Chinese University of Hong Kong | 2025-11-01 |
| Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease (NCT07238985) | Tanta University | 2025-11-01 |
| Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer (NCT07129018) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-11-01 |
| The Antimicrobial Potential of Diclofenac Sodium as an Intracanal Medicament (NCT06207253) | British University In Egypt | 2025-11-01 |
| Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study (NCT07488572) | Sun Yat-sen University | 2025-11-01 |
| The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer (NCT07617246) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2025-11-01 |
| A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC (NCT07244705) | Anbogen Therapeutics, Inc. | 2025-11-01 |
| The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy (NCT07757165) | Fudan University | 2025-11-01 |
| Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer (NCT07172412) | Tianjin Medical University Cancer Institute and Hospital | 2025-11-01 |
| Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution (NCT07075224) | Unither Pharmaceuticals, France | 2025-11-01 |
| Evaluation of the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease (NCT07178678) | University of Saskatchewan | 2025-11-01 |
| RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction (NCT07203521) | Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd | 2025-11-01 |
| New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer (NCT07559760) | The First Hospital of Jilin University | 2025-11-01 |
| A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients (NCT07199777) | SciNeuro | 2025-11-01 |
| hUC-MSC-Exo Therapy for Autoimmune Encephalitis (NCT07131683) | Xuanwu Hospital, Beijing | 2025-11-01 |
| Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors (NCT07337460) | Northern Jiangsu People's Hospital | 2025-11-01 |
| T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis (NCT07152782) | Fudan University | 2025-11-01 |
| Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma (NCT07129772) | The University of Hong Kong | 2025-11-01 |
| BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma (NCT06608940) | Case Comprehensive Cancer Center | 2025-11-01 |
| Comparison Between Tranversus Abdominis Plane (TAP) Block With Only Bupivacaine and TAP Block With Bupivacaine Plus Ketamine in Reducing Postoperative Pain After Total Abdominal Hystrectomy (NCT07482709) | Liaquat National Hospital & Medical College | 2025-11-01 |
| The Role of Islet GLP-1 in the Pathogenesis of Prediabetes (NCT06967558) | Mayo Clinic | 2025-11-01 |
| Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study) (NCT07142044) | EicOsis Human Health Inc. | 2025-11-01 |
| Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer (NCT06829823) | ImmunityBio, Inc. | 2025-11-01 |
| Secondary Prevention of Clostridioides Difficile Using Vancomycin (NCT06979609) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2025-11-01 |
| Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma (NCT07476794) | Sunnybrook Health Sciences Centre | 2025-11-01 |
| A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC (NCT06699121) | LISCure Biosciences | 2025-11-01 |
| Autologous Decidual-like Natural Killer Cells Therapy for Reproductive Failure (NCT07230574) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2025-11-01 |
| Single-dose Prophylactic INdomethacin in Extremely Preterm Infants (NCT06572917) | University of British Columbia | 2025-11-01 |
| Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (NCT07239440) | Dong-A ST Co., Ltd. | 2025-11-01 |
| A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure (NCT07083011) | Mayo Clinic | 2025-11-01 |
| Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors (NCT06144671) | Grit Biotechnology | 2025-11-01 |
| A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis. (NCT06720896) | Aperta Biosciences, LLC | 2025-11-01 |
| Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer (NCT07281157) | Tianjin Medical University Cancer Institute and Hospital | 2025-11-01 |
| Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome (NCT07270549) | CTNNB1 Foundation | 2025-11-01 |
| Study of Intracerebroventricular Injections of Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild-Moderate Alzheimer's Disease (NCT07205601) | Regeneration Biomedical, Inc. | 2025-11-01 |
| Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy (NCT07193160) | Fudan University | 2025-11-01 |
| Hydroxyapatite vs Fluoride Toothpaste for MIH Remineralization (NCT07177053) | Dubai Health | 2025-11-01 |
| Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma (NCT07312578) | Peking University | 2025-11-01 |
| Memantine Hydrochloride in Prostate Cancer Patients (NCT07164794) | Bin Xu | 2025-11-01 |
| Dapagliflozin in Depression (NCT07239011) | Tanta University | 2025-11-01 |
| TAIC FOLFOX for Locally Advanced G/GEJA (NCT07655024) | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 2025-11-01 |
| Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial (NCT07190027) | First Affiliated Hospital of Wenzhou Medical University | 2025-11-01 |
| Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC (NCT07084909) | Lantheus Medical Imaging | 2025-11-01 |
| Clinical Study in Adult Patients With Purulent-inflammatory Processes of the Skin and Soft Tissues, Phase I-II of the Wound Process (NCT06232421) | Research Institute for Physical Chemical Problems of the Belarusian State University | 2025-11-01 |
| Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma (NCT06880601) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2025-11-01 |
| A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers (NCT07233850) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-11-01 |
| Impact of Smell Testing on Health Outcomes (NCT07222891) | Monell Chemical Senses Center | 2025-11-01 |
| Effect Of Silverdiamine Fluoride Gel, Sodium Fluoride With CPP-ACP, APF On Early Childhood Caries - A Randomised Controlled Trial (NCT07371117) | University of Jazan | 2025-11-01 |
| A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension (NCT07142356) | Retension Pharmaceuticals. Inc. | 2025-10-31 |
| Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma (NCT07040280) | Eastern Cooperative Oncology Group | 2025-10-31 |
| A Study With CIT-013 in HS Patients (NCT06993233) | Citryll BV | 2025-10-31 |
| Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC (NCT07110103) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-10-31 |
| FACE Phase II (a Stage II Trial) (NCT07130669) | Stanford University | 2025-10-31 |
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (NCT06393751) | National Cancer Institute (NCI) | 2025-10-31 |